DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 19500/S-014

SUPPLEMENT APPROVAL

Novartis Pharmaceuticals Corporation
Attention: Joseph Zuccarini
Senior Global Program Regulatory Manager
Regulatory Affairs, Established Medicines & Anti-Infectives
One Health Plaza
East Hanover, NJ 07936-1080

Dear Mr. Zuccarini:

Please refer to your Supplemental New Drug Application (sNDA) dated February 2, 2018, received February 2, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lamprene (clofazimine) Capsules.

This Prior Approval supplemental new drug application provides for the following changes to the Prescribing Information:

1. Removal of **RECENT MAJOR CHANGES** from the **HIGHLIGHTS OF PRESCRIBING INFORMATION**.
2. Addition of a **DRUG INTERACTIONS** section to the **HIGHLIGHTS OF PRESCRIBING INFORMATION**.
3. Revisions to the **WARNINGS AND PRECAUTIONS** (5) section, **QT Prolongation** (5.2) subsection and relocation of the information contained in the **Co-Administration with CYP3A Substrates** (5.5) subsection to the **CLINICAL PHARMACOLOGY** (12) section, **Pharmacokinetics** (12.3) subsection.
4. Relocation of the **DRUG INTERACTIONS** (7) section, **Effects of Other Drugs on Clofazimine** (7.3), **Dapsone** (7.4), **Rifampicin** (7.5), and **Isoniazid** (7.6) subsections to the **CLINICAL PHARMACOLOGY** (12) section, **Pharmacokinetics** (12.3) subsection, **Drug Interactions, Clinical Studies** subsection.
5. Relocation of the **DRUG INTERACTIONS** (7) section, **Interactions with QT Prolonging Drugs** (7.1) subsection to the **WARNINGS AND PRECAUTIONS** (5) section, **QT Prolongation** (5.2) subsection.
6. Revisions to the **USE IN SPECIFIC POPULATIONS** (8) section, Severe **Renal Impairment** (8.7) and **Hepatic Impairment** (8.8) subsections.
7. Addition of the **CLINICAL PHARMACOLOGY** (12) section, **Pharmacodynamics** (12.2) subsection.
8. Updated formatting of the **CLINICAL PHARMACOLOGY** (12) section, **Pharmacokinetics** (12.3) subsection.

9. Added a reference to the FDA Susceptibility Test Interpretive Criteria web page to the **CLINICAL PHARMACOLOGY** (12) section, **Microbiology** (12.4) subsection, to be in compliance with the requirements of section 511A of the Federal, Food, Drug and Cosmetic Act.
10. Updates to the **NONCLINICAL TOXICOLOGY** (13) section, **Carcinogenesis, Mutagenesis, and Impairment of Fertility** (13.1) for clarity.
11. Revisions to the **PATIENT COUNSELING INFORMATION, Information for Patients**.
12. Minor editorial edits throughout the Prescribing Information.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at 301-796-0797.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
01/31/2019 02:41:59 PM